XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator, reported its fourth quarter and full-year 2025 financial results, delivering a top and bottom line that exceeded analyst expectations. The company's performance, coupled with significant business development activity and a robust pipeline of future catalysts, appears to have been met with a positive initial market reaction.
Earnings and Revenue Performance Versus Estimates
For the fourth quarter of 2025, XOMA reported a clear beat on both key financial metrics.
- Revenue: The company posted income and revenues of $13.8 million, surpassing the analyst consensus estimate of approximately $11.3 million.
- Earnings Per Share (EPS): XOMA reported a net income of $6.1 million for the quarter. On a per-share basis, the company reported a diluted net income per share attributable to common stockholders of $0.26. This result significantly outperformed the analyst estimate, which had projected a loss of ($0.16) per share.
The full-year 2025 results also showed substantial growth, with total income and revenues reaching $52.1 million, up from $28.5 million in 2024. The company swung to a net income of $31.7 million for the year, compared to a net loss of $13.8 million in the prior year.
Market Reaction and Price Action
The earnings beat has been met with a positive response from investors in pre-market trading. Following the release, XOMA's stock is indicated up approximately 3.7%. This immediate reaction suggests the market views the quarterly outperformance and the company's strategic progress favorably. Over the past month, the stock had already gained roughly 10%, indicating building positive sentiment leading into the earnings announcement.
Key Highlights from the 2025 Report
Beyond the headline financial figures, XOMA's press release emphasized a year of strategic expansion and portfolio strengthening.
- Portfolio Growth and Cash Generation: The company achieved over $50.5 million in total cash receipts for the year, a 9% increase over 2024. This included $33.6 million in royalties and $16.9 million in milestone payments. Royalty receipts alone grew by 68% year-over-year.
- Aggressive Business Development: XOMA added 22 new assets to its portfolio in 2025, including five programs in Phase 2 or Phase 3 development. It also completed or served as the structuring agent in seven company acquisitions, accumulating $11.7 million in non-dilutive capital and securing economic interests in up to $1.1 billion of potential future milestones.
- Strategic Royalty Transaction: A significant amendment to the collaboration with Takeda was highlighted, through which XOMA gained rights to low-to-mid single-digit royalties and up to $852.6 million in potential milestones across nine development-stage assets, including the Phase 3 candidate volixibat.
- Capital Return: Demonstrating confidence in its cash flow, the company repurchased and retired 648,048 shares of its common stock during the year for an aggregate cost of $16.0 million.
- Upcoming Catalysts: Management outlined several key pipeline events anticipated in 2026, including Phase 2b data for volixibat in primary sclerosing cholangitis (PSC), Phase 3 data for ersodetug in tumor hyperinsulinism, and potential European regulatory decisions for OJEMDA™ and MIPLYFFA™.
Looking Ahead: Estimates and Outlook
While the press release did not provide specific quantitative financial guidance for 2026, it expressed an optimistic outlook based on the growing portfolio and anticipated clinical and regulatory milestones. The company stated that with 14 programs in registrational studies, it expects "growing free cash flow in 2027 and beyond."
Current analyst estimates project the company's revenue to reach approximately $65.2 million for the full year 2026. For the upcoming first quarter of 2026, analysts are estimating revenue of about $13.1 million and an EPS loss of ($0.16). Investors will be watching the progression of XOMA's key clinical readouts and royalty ramp-ups to gauge alignment with these projections.
For a detailed view of historical earnings and future analyst projections, you can review the data on the XOMA Earnings and XOMA Analyst Forecasts pages.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. The data presented is based on publicly available information and analyst estimates, which are subject to change. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.